Real-world experience with IDH inhibitors in pediatric patients with <i>IDH1</i>- and <i>IDH2</i>-mutated acute myeloid leukemia and myelodysplastic syndrome

Documenti analoghi

• Safety profiles of IDH inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
  di: Ximu Sun, et al.
  Pubblicazione: (2025-02-01)
• Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: a systematic review and meta-analysis
  di: Xiu Chen, et al.
  Pubblicazione: (2023-07-01)
• Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
  di: Danielle Golub, et al.
  Pubblicazione: (2019-05-01)
• IDH1 inhibitor-induced neutrophilic dermatosis in a patient with acute myeloid leukemia
  di: Sydney Dunn-Valadez, et al.
  Pubblicazione: (2022-01-01)
• IDH1-mutated relapsed or refractory AML: current challenges and future prospects
  di: Megías-Vericat JE, et al.
  Pubblicazione: (2019-06-01)